X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (24436) 24436
Book Review (5380) 5380
Publication (1470) 1470
Newsletter (69) 69
Conference Proceeding (59) 59
Magazine Article (41) 41
Book Chapter (33) 33
Newspaper Article (12) 12
Dissertation (9) 9
Book / eBook (3) 3
Transcript (2) 2
Web Resource (2) 2
Data Set (1) 1
Presentation (1) 1
Streaming Video (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (22472) 22472
index medicus (22110) 22110
interferon-alpha - therapeutic use (14705) 14705
male (12396) 12396
female (11817) 11817
middle aged (10024) 10024
adult (9452) 9452
antiviral agents - therapeutic use (8118) 8118
recombinant proteins (7040) 7040
interferon-alpha (6014) 6014
treatment outcome (6011) 6011
aged (5491) 5491
hepatitis c, chronic - drug therapy (5200) 5200
ribavirin - therapeutic use (4721) 4721
interferon (4474) 4474
drug therapy, combination (4306) 4306
oncology (4187) 4187
gastroenterology & hepatology (4059) 4059
interferon-alpha - administration & dosage (3799) 3799
therapy (3508) 3508
polyethylene glycols - therapeutic use (3503) 3503
interferon-alpha - adverse effects (3359) 3359
hepatitis c (3077) 3077
hepacivirus - genetics (2789) 2789
antineoplastic agents - therapeutic use (2735) 2735
ribavirin (2464) 2464
animals (2385) 2385
genotype (2295) 2295
hepatitis c - drug therapy (2223) 2223
hepatitis c virus (2199) 2199
abridged index medicus (2177) 2177
recombinant proteins - therapeutic use (2142) 2142
care and treatment (2124) 2124
immunology (2109) 2109
biological response modifiers (2072) 2072
cancer (2038) 2038
antineoplastic combined chemotherapy protocols - therapeutic use (2006) 2006
adolescent (1936) 1936
health aspects (1907) 1907
virus-infection (1862) 1862
antiviral agents - adverse effects (1855) 1855
infection (1813) 1813
pharmacology & pharmacy (1803) 1803
interferon alpha-2 (1788) 1788
hematology (1764) 1764
interferon alpha (1738) 1738
time factors (1701) 1701
prognosis (1636) 1636
hepatitis c, chronic - virology (1624) 1624
retrospective studies (1580) 1580
follow-up studies (1579) 1579
virology (1568) 1568
infectious diseases (1559) 1559
antiviral agents - administration & dosage (1526) 1526
viral load (1499) 1499
hepatitis (1463) 1463
drug therapy (1439) 1439
rna, viral - blood (1412) 1412
carcinoma, renal cell - drug therapy (1383) 1383
hepacivirus - drug effects (1381) 1381
kidney neoplasms - drug therapy (1364) 1364
prospective studies (1302) 1302
combined modality therapy (1268) 1268
immunotherapy (1267) 1267
analysis (1255) 1255
mice (1250) 1250
risk factors (1240) 1240
interferon-alpha - pharmacology (1233) 1233
research (1227) 1227
plus ribavirin (1216) 1216
hepatitis c, chronic - complications (1210) 1210
medicine, general & internal (1199) 1199
hepatitis b, chronic - drug therapy (1167) 1167
ribavirin - administration & dosage (1147) 1147
young adult (1113) 1113
aged, 80 and over (1085) 1085
drug administration schedule (1080) 1080
recurrence (1061) 1061
survival (1060) 1060
ribavirin - adverse effects (1019) 1019
kidney neoplasms - pathology (1013) 1013
medicine & public health (1005) 1005
expression (990) 990
chemotherapy (960) 960
combination (956) 956
dose-response relationship, drug (952) 952
child (930) 930
hepatitis c - therapy (928) 928
hepatitis c - complications (919) 919
trial (910) 910
remission induction (905) 905
combination therapy (899) 899
chronic hepatitis-c (883) 883
liver (875) 875
cytokines (874) 874
hepacivirus - isolation & purification (874) 874
alanine transaminase - blood (872) 872
chronic myelogenous leukemia (868) 868
polyethylene glycols - administration & dosage (855) 855
chronic disease (854) 854
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (22114) 22114
French (477) 477
German (353) 353
Japanese (319) 319
Chinese (312) 312
Spanish (293) 293
Russian (249) 249
Polish (127) 127
Italian (85) 85
Hungarian (57) 57
Korean (35) 35
Czech (25) 25
Dutch (23) 23
Portuguese (22) 22
Serbian (15) 15
Danish (12) 12
Swedish (10) 10
Croatian (9) 9
Hebrew (9) 9
Finnish (7) 7
Ukrainian (7) 7
Norwegian (6) 6
Slovak (6) 6
Romanian (5) 5
Turkish (5) 5
Bulgarian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 02/2012, Volume 30, Issue 5, pp. 482 - 487
Journal Article
Annals of Internal Medicine, ISSN 0003-4819, 03/2015, Volume 162, Issue 6, pp. 407 - 419
Journal Article
Hepatology, ISSN 0270-9139, 03/2012, Volume 55, Issue 3, pp. 742 - 748
Journal Article
Lancet, The, ISSN 0140-6736, 2014, Volume 384, Issue 9956, pp. 1756 - 1765
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2011, Volume 364, Issue 13, pp. 1207 - 1217
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2013, Volume 368, Issue 20, pp. 1878 - 1887
Journal Article
Journal Article
Journal of Clinical Investigation, ISSN 0021-9738, 01/2011, Volume 121, Issue 1, pp. 308 - 317
Chronic infection with hepatitis C virus (HCV) is a major public health problem, with nearly 170 million infected individuals worldwide Current treatment for... 
MEDICINE, RESEARCH & EXPERIMENTAL | LIVER INFLAMMATION | GAMMA-INDUCIBLE PROTEIN-10 | VIRUS-INFECTION | DIPEPTIDYL-PEPTIDASE-IV | ANTIVIRAL THERAPY | INSULIN-RESISTANCE | IMMUNE-RESPONSES | CHRONIC HEPATITIS-C | LEVELS CORRELATE | PEGINTERFERON PLUS RIBAVIRIN | Chemokine CXCL10 - blood | Prognosis | Antiviral Agents - therapeutic use | Receptors, CXCR3 - blood | Humans | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Chemokine CXCL10 - antagonists & inhibitors | Dipeptidyl Peptidase 4 - blood | Hepatitis C, Chronic - virology | Hepatitis C, Chronic - therapy | Recombinant Proteins | Hepatitis C, Chronic - blood | Polyethylene Glycols - therapeutic use | T-Lymphocytes - virology | Treatment Failure | Hepatitis C, Chronic - immunology | Peptide Fragments - blood | Protein Array Analysis | T-Lymphocytes - immunology | Proteases | Physiological aspects | Research | Diagnosis | Hepatitis C | Drug therapy | Chemokines | Index Medicus | Abridged Index Medicus | Hepatitis C, Chronic/therapy | T-Lymphocytes/immunology | Polyethylene Glycols/therapeutic use | Dipeptidyl Peptidase 4/blood | Receptors, CXCR3/blood | Chemokine CXCL10/blood | T-Lymphocytes/virology | Hepatitis C, Chronic/blood | Interferon-alpha/therapeutic use | Chemokine CXCL10/antagonists & inhibitors | Life Sciences | Immunology | Antiviral Agents/therapeutic use | Hepatitis C, Chronic/immunology | Peptide Fragments/blood | Ribavirin/therapeutic use | Hepatitis C, Chronic/virology
Journal Article
Gastroenterology, ISSN 0016-5085, 2014, Volume 146, Issue 7, pp. 1669 - 1679.e3
Background & Aims Simeprevir is an oral, once-daily inhibitor of hepatitis c virus (HCV) protease NS3/4A. We investigated the safety and efficacy of simeprevir... 
Gastroenterology and Hepatology | Drug | Chronic Hepatitis C | DAA | PROMISE | ALPHA-2A | PLUS RIBAVIRIN | VIRUS-INFECTION | TELAPREVIR | MANAGEMENT | CHRONIC HEPATITIS-C | PEGYLATED INTERFERON | BOCEPREVIR | RETREATMENT | GASTROENTEROLOGY & HEPATOLOGY | ONCE-DAILY TMC435 | Recombinant Proteins - therapeutic use | Recurrence | Simeprevir | Hepatitis C - drug therapy | Humans | Middle Aged | Hepacivirus - genetics | Polyethylene Glycols - adverse effects | Male | RNA, Viral - blood | Recombinant Proteins - adverse effects | North America | Polyethylene Glycols - therapeutic use | Viral Load | Young Adult | Time Factors | Hepatitis C - blood | Protease Inhibitors - adverse effects | Adult | Female | Drug Therapy, Combination | Protease Inhibitors - therapeutic use | Hepacivirus - drug effects | Double-Blind Method | Antiviral Agents - therapeutic use | Europe | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Treatment Outcome | Biomarkers - blood | Hepatitis C - diagnosis | Hepacivirus - enzymology | Sulfonamides - therapeutic use | Asia | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Heterocyclic Compounds, 3-Ring - adverse effects | Heterocyclic Compounds, 3-Ring - therapeutic use | Sulfonamides - adverse effects | Hepacivirus - growth & development | Viral Nonstructural Proteins - metabolism | Aged | Interferon-alpha - adverse effects | Viral Nonstructural Proteins - antagonists & inhibitors | Medical colleges | Care and treatment | Proteases | Interferon alpha | Clinical trials | Product development | Genetic aspects | Biological response modifiers | Hepatitis C virus | Hepatitis C | Health aspects | Ribavirin | Index Medicus | Abridged Index Medicus | Life Sciences
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 2014, Volume 32, Issue 8, pp. 760 - 767
Purpose This international phase III trial (Investigating Torisel As Second-Line Therapy [INTORSECT]) compared the efficacy of temsirolimus (mammalian target... 
SURVIVAL | INTERFERON-ALPHA | EVEROLIMUS | ONCOLOGY | BEVACIZUMAB | DOUBLE-BLIND | AGENTS | Niacinamide - analogs & derivatives | TOR Serine-Threonine Kinases - metabolism | Humans | Middle Aged | Male | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | TOR Serine-Threonine Kinases - antagonists & inhibitors | Young Adult | Receptors, Vascular Endothelial Growth Factor - metabolism | Time Factors | Phenylurea Compounds - adverse effects | Treatment Failure | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors | Adult | Carcinoma, Renal Cell - enzymology | Female | Carcinoma, Renal Cell - drug therapy | Pyrroles - therapeutic use | Angiogenesis Inhibitors - adverse effects | Sirolimus - adverse effects | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Kaplan-Meier Estimate | Niacinamide - adverse effects | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Kidney Neoplasms - mortality | Disease Progression | Carcinoma, Renal Cell - mortality | Disease-Free Survival | Protein Kinase Inhibitors - therapeutic use | Carcinoma, Renal Cell - secondary | Kidney Neoplasms - enzymology | Indoles - therapeutic use | Kidney Neoplasms - pathology | Aged | Kidney Neoplasms - drug therapy | Index Medicus | ORIGINAL REPORTS
Journal Article